Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | MAP3K14 | Q99558 | 10/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485608 | 0.89 | MAP3K5 (0.39) | PIK3CAPIK3CBPIK3CGPIK3CDMAP3K14 | |
| SCHEMBL1485090 | 0.84 | PIK3CA (0.54) | PIK3CAPIK3CBPIK3CGPIK3CDMAP3K14 | |
| SCHEMBL12538834 | 0.80 | MAP3K14 (0.42) | PIK3CDMAP3K14MAP3K5 | |
| SCHEMBL1485427 | 0.80 | MAP3K14 (0.64) | PIK3CDMAP3K14PIK3R1 | |
| SCHEMBL1485607 | 0.80 | MAP3K14 (0.45) | PIK3CAPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL12689121 | 0.76 | CYP2C9 (0.45) | PIK3CAPIK3CDMAP3K14PIK3R1 | |
| SCHEMBL12693205 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CGPIK3CDMAP3K14 | |
| SCHEMBL1485055 | 0.76 | PIK3CA (0.42) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL12693211 | 0.75 | PIK3CA (0.46) | PIK3CAPIK3CBPIK3CGPIK3CDMAP3K14 | |
| SCHEMBL12539133 | 0.75 | PIK3CD (0.40) | PIK3CAPIK3CDMAP3K14PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2711368-B1 | Benzoxazepin PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CB 17/4885PIK3CG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.